KALV — Kalvista Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $501.62m
- $426.03m
2019 April 30th | 2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -20.8 | -29.1 | -46.2 | -82.3 | -92.9 |
Depreciation | |||||
Non-Cash Items | 2.86 | 4.43 | 7.19 | 16 | 9.52 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -18.8 | -20.6 | 8.35 | -12.3 | 7.41 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -36.4 | -44.8 | -30.2 | -78.1 | -75.3 |
Capital Expenditures | -1.08 | -0.22 | -0.082 | -0.931 | -1.2 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -68.3 | 17 | -148 | 58.8 | 42.6 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -69.4 | 16.8 | -148 | 57.9 | 41.4 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 87.9 | 11.6 | 212 | 1.58 | 58.1 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -19 | -16.2 | 34.8 | -19.9 | 25.5 |